Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo® (nivolumab) in anti-PD1 Failed Melanoma

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs